Replies to post #199301 on Biotech Values

[xavierprivas]

It does not save any money compared to the autologous T-cells.
These allogeneic T-cells still come from a donor, it is not really off the
shelf like Cellectis, thus it is not a threat for Juno, Kite, etc.

I have no position in Cellectis because I think it has low probability for success IMO.

[DewDiligence]

JUNO phase-2 trial in ALL on FDA clinical hold:

http://finance.yahoo.com/news/juno-therapeutics-reports-clinical-hold-200500756.html

Juno Therapeutics, Inc…today announced that it has received notice from the U.S. Food and Drug Administration that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the “ROCKET” trial. The clinical hold was initiated after two patient deaths last week, which followed the recent addition of fludarabine to the pre-conditioning regimen.